# Inflammatory Myopathies: Dermatomyositis, Polymyositis, and IBM
## Overview
The inflammatory myopathies (idiopathic inflammatory myopathies, IIM) are a heterogeneous group of autoimmune muscle diseases. The major subtypes include dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome, overlap myositis, inclusion body myositis (IBM), and polymyositis (PM). Polymyositis is now considered a diagnosis of exclusion and is rare; many cases previously diagnosed as PM have been reclassified as IMNM, overlap myositis, or IBM with modern antibody testing and biopsy interpretation. The overall prevalence is approximately 5-22 per 100,000. Recognition of myositis-specific antibodies (MSAs) has transformed the classification and management of these conditions.
## Dermatomyositis (DM)
### Clinical Features
Dermatomyositis presents with proximal symmetric weakness affecting the shoulder and hip girdles, causing difficulty rising from chairs, climbing stairs, and lifting arms overhead. The characteristic skin manifestations may precede or accompany the weakness. The heliotrope rash is a violaceous (purplish) discoloration of the upper eyelids with periorbital edema. Gottron papules are erythematous-violaceous papules over the MCPs, PIPs, and DIPs (knuckles), while the Gottron sign is a macular erythema over extensor surfaces such as elbows and knees. The V-sign is an erythematous rash on the anterior neck and upper chest, and the shawl sign describes a similar rash on the upper back and shoulders. Mechanic's hands present as cracked, roughened skin on the lateral and palmar surfaces of the fingers. Nail fold capillary changes show dilated capillary loops with dropout. The holster sign is a rash on the lateral thighs. Clinically amyopathic DM (CADM) describes classic skin findings without clinically significant weakness; it may have elevated CK or abnormal MRI and includes hypomyopathic (subclinical weakness) and amyopathic (no weakness at all) forms.
### Dermatomyositis-Specific Antibodies
| Antibody | Phenotype | Cancer Risk | Prognosis |
|---|---|---|---|
| Anti-Mi-2 | Classic DM (skin + weakness) | Low | Good; responds to therapy |
| Anti-TIF1-gamma | Severe skin disease | Very high (~60% in adults) | Depends on cancer |
| Anti-NXP2 (MJ) | DM + calcinosis (children); cancer (adults) | High (adults) | Variable |
| Anti-MDA5 | Amyopathic DM + RP-ILD + skin ulcers | Low | Poor if RP-ILD develops |
| Anti-SAE | Skin → weakness, dysphagia | Moderate | Variable |
| Anti-SRP (IMNM) | Severe proximal weakness, cardiac | Rare | Poor; refractory |
| Anti-HMGCR (IMNM) | Statin-triggered necrotizing myopathy | Rare (if no statin exposure) | Moderate; requires immunosuppression |
| Anti-Jo-1 (antisynthetase) | Myositis + ILD + arthritis | Low | Depends on ILD |
Anti-Mi-2 is associated with classic DM with a good prognosis and excellent response to therapy. Anti-NXP2 (MJ) is associated with DM with calcinosis (especially in children) and cancer risk in adults. Anti-TIF1-gamma (p155/140) carries a strong association with malignancy in adults (up to 60% cancer risk) and often presents with severe skin disease. Anti-MDA5 (CADM-140) is associated with clinically amyopathic DM accompanied by rapidly progressive interstitial lung disease (RP-ILD), skin ulceration, and arthritis, with poor prognosis if RP-ILD develops. Anti-SAE is found in adult DM that may begin with skin disease and then develop weakness, with dysphagia being common.
### Cancer Association
Cancer risk is elevated in DM, especially in adults over 40 years of age, with the highest risk within 3 years of diagnosis (both before and after). The most common associated malignancies include ovarian, lung, breast, gastrointestinal, and nasopharyngeal cancers (the last particularly in Asian populations). Anti-TIF1-gamma and anti-NXP2 carry the highest cancer risk. Screening should include CT of the chest, abdomen, and pelvis, age-appropriate cancer screening (mammography, colonoscopy), CA-125, and PET-CT in high-risk patients.
Clinical photographs showing the characteristic skin findings of dermatomyositis including heliotrope rash, Gottron papules, V-sign, and mechanic's hands
## Immune-Mediated Necrotizing Myopathy (IMNM)
### Clinical Features
IMNM presents with severe proximal weakness that is often acute or subacute in onset. CK is markedly elevated, often above 5000 IU/L and sometimes exceeding 10,000. There is minimal or no skin involvement. It can be triggered by statin exposure (anti-HMGCR subtype) or occur de novo.
### Antibodies
Anti-SRP (signal recognition particle) antibodies are associated with severe, rapidly progressive weakness, cardiac involvement, and poor response to therapy; there is no statin association. Anti-HMGCR antibodies define statin-associated IMNM, which does not resolve with statin discontinuation because it is an autoimmune process, not a toxic one. The weakness may be severe. Cancer risk exists in older anti-HMGCR positive patients who have not taken statins.
### Muscle Biopsy
Biopsy in IMNM shows myofiber necrosis and regeneration with minimal inflammatory infiltrate. Macrophage-predominant invasion of non-necrotic fibers is seen. There is no perifascicular atrophy, which distinguishes it from DM. Complement (MAC/C5b-9) deposition on the sarcolemma is characteristic, especially in anti-SRP cases.
## Antisynthetase Syndrome
### Clinical Features -- The Classic Triad
The classic triad consists of myositis (proximal weakness with elevated CK), interstitial lung disease (which can be chronic NSIP pattern or acute/subacute and is the major cause of morbidity and mortality), and inflammatory arthritis (non-erosive, symmetric polyarthritis often affecting the hands). Additional features include mechanic's hands, Raynaud phenomenon, and fever.
### Antibodies
Anti-Jo-1 is the most common antisynthetase antibody, present in 20-30% of IIM patients with ILD. Others include anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS, anti-Ha, and anti-Zo. Anti-Jo-1 has the strongest myositis component, while other antisynthetase antibodies may present predominantly with ILD rather than muscle disease.
### ILD Assessment
High-resolution CT of the chest most commonly shows an NSIP pattern, though UIP or organizing pneumonia patterns are also seen. Pulmonary function tests reveal a restrictive pattern with reduced FVC and DLCO. Early pulmonary involvement screening is essential in all patients with antisynthetase syndrome.
## Inclusion Body Myositis (IBM)
### Clinical Features
IBM is the most common inflammatory myopathy in patients over 50 years of age, with a 3:1 male predominance. It has a distinctive pattern of weakness that preferentially affects finger flexors (FDP), producing inability to make a tight fist and weak grip; quadriceps, causing knee buckling, difficulty with stairs, and falls; and wrist flexors and ankle dorsiflexors. Unlike DM and other inflammatory myopathies, IBM weakness is asymmetric. Dysphagia occurs in up to 60% of patients. Progression is slow and insidious over years to decades. CK is only mildly elevated (typically less than 10 times normal) or may be normal.
### Diagnosis
Anti-cN1A (cytoplasmic 5'-nucleotidase 1A) antibodies are present in approximately 30-50% of IBM patients. They are not perfectly specific (also seen in Sjogren syndrome and lupus) but support the diagnosis in the right clinical context. Muscle biopsy is definitive and shows rimmed vacuoles, endomysial inflammation with invasion of non-necrotic fibers by CD8+ T cells, congophilic (amyloid) inclusions, and mitochondrial changes (COX-negative/SDH-positive fibers). EMG demonstrates mixed myopathic and neuropathic features, described as an "irritable myopathy" with fibrillation potentials.
### Treatment
IBM is resistant to immunosuppressive therapy, which represents the cardinal management challenge. IVIG, corticosteroids, methotrexate, and other immunosuppressants do not provide sustained benefit. Some patients receive an empiric immunotherapy trial, which should be discontinued if no objective improvement occurs after 6 months. Management is therefore supportive, relying on physical therapy, occupational therapy, and swallowing therapy. Assistive devices are used for falls prevention. Cricopharyngeal myotomy or botulinum toxin may provide temporary benefit for severe dysphagia. Emerging therapies including anti-KLRG1 antibodies, follistatin gene therapy, and other approaches are in early clinical trials.
Muscle biopsy histopathology comparing dermatomyositis (perifascicular atrophy, perivascular inflammation) with IBM (rimmed vacuoles, endomysial CD8+ T-cell invasion, congophilic inclusions)
## Diagnostic Approach
### Laboratory Studies
CK is elevated in all IIMs except some cases of CADM and IBM; the highest levels (above 10,000) occur in IMNM. Aldolase may be elevated when CK is normal, especially in fasciitis-predominant disease. ESR and CRP are variably elevated but not specific. The myositis-specific antibody panel is essential for classification and prognostication. ANA is positive in many IIMs but is not specific.
### Electrodiagnosis
EMG demonstrates myopathic motor unit potentials that are small in amplitude, short in duration, and polyphasic with early recruitment. Increased insertional activity with fibrillation potentials and positive sharp waves indicates active or irritable myopathy. Complex repetitive discharges are seen especially in IBM. Sensory nerve conduction studies are normal.
### MRI
STIR and T2 fat-suppressed sequences demonstrate muscle edema representing active inflammation, while T1 sequences show fatty infiltration indicating chronic damage. MRI is useful for guiding biopsy site selection (an affected but not end-stage muscle should be chosen). Thigh MRI is most informative for most IIMs, while forearm MRI is preferred in IBM.
### Muscle Biopsy
In DM, biopsy shows perifascicular atrophy (which is pathognomonic), perivascular and perimysial B-cell and CD4+ T-cell inflammation, and complement (MAC) deposition on capillaries. In IMNM, biopsy reveals necrotic and regenerating fibers with macrophage-predominant and minimal lymphocytic inflammation. In IBM, rimmed vacuoles, endomysial CD8+ T-cell invasion of non-necrotic fibers, congophilic inclusions, and mitochondrial changes are seen. PM shows endomysial CD8+ T-cell invasion of non-necrotic fibers without rimmed vacuoles and remains a diagnosis of exclusion.
## Treatment of DM, IMNM, and Antisynthetase Syndrome
### First-Line
Corticosteroids are the backbone of initial therapy, with prednisone started at 1 mg/kg/day (maximum approximately 80 mg) and tapered over months guided by clinical response and CK levels. A steroid-sparing agent should be initiated early, with methotrexate (10-25 mg/week) or azathioprine (2-3 mg/kg/day) being first choices, and mycophenolate mofetil serving as an alternative.
### Refractory Disease
IVIG is effective in DM (demonstrated in the Dalakas RCT) and IMNM, and is often used as a steroid-sparing agent. Rituximab is effective in many refractory cases, especially antisynthetase syndrome and anti-SRP IMNM (the RIM trial showed a trend toward benefit). Cyclophosphamide is reserved for severe ILD or refractory disease. Tacrolimus and cyclosporine are used especially for the ILD component.
### ILD Management
First-line therapy for ILD consists of high-dose corticosteroids combined with mycophenolate or tacrolimus. Rituximab is used for refractory ILD. Anti-MDA5 RP-ILD requires aggressive combination therapy (triple therapy with steroids, a calcineurin inhibitor, and cyclophosphamide), with tofacitinib (a JAK inhibitor) showing promise. Lung transplantation is considered in severe refractory cases.
## Clinical Pearls
Proximal weakness plus skin rash in an adult equals dermatomyositis until proven otherwise, and malignancy screening is mandatory (especially if anti-TIF1-gamma is positive). Finger flexor weakness (weak grip with relatively preserved finger extension) in an older man should prompt IBM as the first consideration, not PM. If a patient diagnosed with "PM" does not respond to immunotherapy after 6 months, the diagnosis should be reconsidered: the patient most likely has IBM, IMNM, or a muscular dystrophy. Anti-MDA5 DM with rapidly progressive ILD is a medical emergency where early aggressive immunosuppression (including JAK inhibitors) can be life-saving. Statin-associated anti-HMGCR myopathy does not resolve with statin discontinuation because it is an autoimmune disease requiring immunosuppression. CK level does not always correlate with disease severity: IBM often has mild CK elevation despite significant weakness, while early treatment may normalize CK while weakness persists. PFTs and HRCT chest should always be performed in patients with antisynthetase syndrome antibodies, even if they are asymptomatic, because ILD may be subclinical. The term "polymyositis" is increasingly considered a diagnosis of exclusion, as modern antibody testing and biopsy interpretation reclassify most cases as IMNM, antisynthetase syndrome, or overlap myositis.
## References
- Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86.
- Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol. 2019;15(5):257-272.
- Allenbach Y, Mammen AL, Benveniste O, Stenzel W. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies. Neuromuscul Disord. 2018;28(1):87-99.
- Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734-1747.
- Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280(1):8-23.